Search

Your search keyword '"P. L. Zinzani"' showing total 225 results
Start Over Author "P. L. Zinzani"
225 results on '"P. L. Zinzani"'

1. S101: GENETIC AND EPIGENETIC FACTORS DRIVING PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATHOGENESIS AND OUTCOME

Author

D. Noerenberg, F. Briest, C. Hennch, K. Yoshida, J. Nimo, R. Hablesreiter, Y. Takeuchi, D. Sasca, H. Ueno, L. Mansouri, Y. Inoue, L. Wiegand, A. M. Staiger, B. Casadei, M. Ziepert, F. Asmar, P. Korkolopoulou, M. Kirchner, P. Mertins, J. Weiner, E. Toth, T. Weber, A. Warth, T. Schneider, R.-M. Amini, W. Klapper, M. Hummel, V. Poeschel, G. Kanellis, A. Rosenwald, G. Held, E. Campo, K. Stamatopoulos, I. Anagnostopoulos, L. Bullinger, N. Goldschmidt, P. L. Zinzani, C. Bödor, R. Rosenquist, T. P. Vassilakopoulos, G. Ott, S. Ogawa, and F. Damm

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

2. S208: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING (ID) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF THE GLOBAL PHASE 2 STUDY TIDAL

Author

A. Zelenetz, W. Jurczak, V. Ribrag, K. Linton, G. Collins, J. Lopéz-Jiménez, N. Reddy, A. Mengarelli, T. Phillips, G. Musuraca, O. Sheehy, J. Li, W. Xu, M. Azoulay, R. Ghalie, and P. L. Zinzani

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

3. S217: PRELIMINARY ANALYSIS OF THE PHASE II STUDY USING TOLINAPANT (ASTX660) MONOTHERAPY IN 98 PERIPHERAL T-CELL LYMPHOMA AND 51 CUTANEOUS T-CELL LYMPHOMA SUBJECTS WITH RELAPSED REFRACTORY DISEASE.

Author

J.-M. Michot, A. Mehta, F. Samaniego, E. Bachy, P. L. Zinzani, A. Prica, G. P. Colins, V Ribrag, N. Wagner-Johnston, D. El-Sharkawi, O. A. O’Connor, R. Wilcox, L. Wang, L. Wilson, M. Sims, J. A. Taylor, H. N. Keer, and F. Foss

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

4. S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL

Author

P. L. Zinzani, J. Mayer, R. Auer, F. Bijou, A. C. de Oliveira, C. R. Flowers, M. Merli, K. Bouabdallah, P. S. Ganly, Y. Song, H. Zhang, R. Johnson, A. M García-Sancho, M. Provencio, M. Trněný, S. Yuen, H. Tilly, E. Kingsley, G. Tuyman, S. E. Assouline, E. Ivanova, P. Kim, J. Huang, R. Delarue, and J. Trotman

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

6. P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY

Author

A. F. Herrera, D. Lavie, N. A. Johnson, A. Avigdor, P. Borchmann, C. Andreadis, A. Bazargan, G. Gregory, C. Keane, T. Inna, V. Vucinic, P. L. Zinzani, H. Zhang, P. Pillai, P. Marinello, and J. Timmerman

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

8. P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

Author

T. A. Eyre, M. L. Wang, N. N. Shah, A. J. Alencar, J. N. Gerson, M. R. Patel, B. Fakhri, E. Vandenberghe, W. Jurczak, X. N. Tan, K. L. Lewis, T. Fenske, Y. Wang, C. C. Coombs, I. Flinn, D. Lewis, S. Le Gouill, M. Gandhi, C. Chay, M. L. Palomba, J. A. Woyach, J. M. Pagel, N. Lamanna, J. P. Sharman, D. J. Andorsky, J. B. Cohen, M. A. Barve, P. Ghia, M. Yin, P. L. Zinzani, C. Ujjani, Y. Koh, K. Izutsu, E. Lech-Maranda, J. Kherani, C. Tam, S. Sundaram, B. Nair, D. E. Tsai, M. Balbas, A. R. Mato, and C. Y. Cheah

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

10. P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL

Author

P. L. Zinzani, S. M. Ansell, F. Bosch, J. W. Friedberg, J. P. Marolleau, L. Arcaini, R. Garcia-Sanz, A. K. Gopal, C. Grande, R. Merryman, A. Pinto, S. D. Smith, J. C. Villasboas, D. Wallace, J. Fagerberg, J. G. Magalhaes, and P. Armand

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

11. P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL

Author

P. L. Zinzani, M. Özcan, K. Sapunarova, W. Jurczak, A. Hamed, K. Bouabdallah, G. Saydam, K. Geissler, Á. Szomor, M. Lazaroiu, A. Salar, A. Tempescul, M. Nalcaci, L. Gercheva, M. Egyed, P. Panayiotidis, L. Mongay Soler, A. Cao, C. Phelps, B. H Childs, and M. J Matasar

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

12. P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS

Author

P. L. Zinzani, MD, PhD, J. Zain, MD, M. Mead, BS, MD, C. Casulo, MD, E. D. Jacobsen, MD, G. Gritti, MD, PhD, L. Pinter-Brown, MD, K. Isutzu, MD, D. Cohan, MD, M. Daugherty, PharmD, J. E. Brammer, MD, N. Mehta-Shah, MD, B. Pro, MD, and S. M. Horwitz, MD

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

14. P1198: ASSOCIATION OF PRETREATMENT TUMOR CHARACTERISTICS AND CLINICAL OUTCOMES FOLLOWING SECOND-LINE AXICABTAGENE CILOLEUCEL VS STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

Author

F. L. Locke, J. Chou, S. Vardhanabhuti, R. Perbost, P. Dreger, B. T. Hill, C. Lee, P. L. Zinzani, N. Kröger, A. López-Guillermo, H. Greinix, W. Zhang, G. Tiwari, C. To, P. Cheng, A. Bot, R. Shen, S. Filosto, and J. Galon

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

15. P1239: TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTORY MATURE T- AND NK-CELL NEOPLASMS: RESULTS FROM A PHASE 2 STUDY

Author

E. Bachy, K. J. Savage, H. Huang, Y. L. Kwong, G. Gritti, Q. Zhang, A. M. Liberati, J. Cao, H. Yang, S. Hao, J. Hu, K. Zhou, F. Russo, H. Zhang, W. Sang, J. Ji, A. J. M. Ferreri, G. L. Damaj, H. Liu, W. Zhang, X. Ke, C. Ghiggi, S. Huang, X. Li, H. Yao, J. Paik, W. Novotny, W. Zhou, H. Zhu, J. Huang, and P. L. Zinzani

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

16. P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY

Author

S. Opat, B. Hu, A. Tedeschi, K. M. Linton, P. McKay, H. Chan, J. Jin, M. Sun, M. Sobieraj-Teague, P. L. Zinzani, M. Coleman, P. Browett, X. Ke, C. A. Portell, C. Thieblemont, K. Ardeshna, F. Bijou, P. Walker, E. A. Hawkes, S.-J. Ho, K.-S. Zhou, M. Co, J. Xu, Z. Liang, J. Anderson, C. Tankersley, J. Huang, and J. Trotman

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

21. The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study

Author

Andrew D. Zelenetz, Wojciech Jurczak, Vincent Ribrag, Kim Linton, Graham P. Collins, Javier L. Jiménez, Mark Bishton, Bhagirathbhai Dholaria, Andrea Mengarelli, Tycel J. Phillips, Nagendraprasad Sungala, Gerardo Musuraca, Oonagh Sheehy, Eric Van Den Neste, Mitsuhiko Odera, Lu Miao, Daniel P. Gold, Richard G. Ghalie, and Pier L. Zinzani

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Abstract In this global phase 2 study in patients with relapsed/refractory follicular lymphoma (FL), zandelisib was administered on intermittent dosing to mitigate immune‐related adverse events and infections that have been reported with oral PI3Kδ inhibitors administered daily continuously. Eligible patients with measurable disease and progression after at least two prior therapies were administered zandelisib until disease progression or intolerability. The primary efficacy endpoint was objective response rate (ORR) and the key secondary efficacy endpoint was duration of response (DOR). We report on 121 patients with FL administered zandelisib on intermittent dosing after 8 weeks of daily dosing for tumor debulking. The median number of prior therapies was 3 (range, 2–8) and 45% of patients had refractory disease. The ORR was 73% (95% confidence interval [CI], 63.9–80.4), the complete response (CR) rate was 38% (95% CI, 29.3–47.3), and the median DOR was 16.4 months (95% CI, 9.5–not reached). With a median follow‐up of 14.3 months (range, 1–30.5), the median progression‐free survival was 11.6 months (95% CI, 8.3–not reached). Twenty‐one patients (17%) discontinued therapy due to an adverse event. Grade 3–4 class‐related toxicities included 6% diarrhea, 5% lung infections, 3% colitis (confirmed by biopsy or imaging), 3% rash, 2% AST elevation, and 1% non‐infectious pneumonitis. Zandelisib achieved a high rate of durable responses in heavily pretreated patients with relapsed/refractory FL. The intermittent dosing resulted in a relatively low incidence of severe class‐related toxicities, which supports the evaluation of zandelisib as a single agent and in combination with indolent B‐cell malignancies.

Published
2024
Full Text
View/download PDF

22. Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe

Author

Mark J. Bishton, Gilles Salles, Camille Golfier, Wolfgang Knauf, Monica Bocchia, Deborah Turner, Borhane Slama, Jatinder Harchowal, Scott Marshall, Alberto Bosi, Juan José Bargay Lleonart, Manfred Welslau, SooKyoung Kim, Young N. Lee, Pier L. Zinzani, and Kamel Laribi

Subjects
biosimilar, DLBCL, NHL, rituximab, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Abstract The rituximab biosimilar CT‐P10 is approved for the treatment of non‐Hodgkin lymphoma. Previous studies have demonstrated clinical similarity between CT‐P10 and reference rituximab. However, real‐world data relating to treatment in patients with DLBCL with rituximab biosimilars are limited. This study collected real‐world data relating to the effectiveness and safety of CT‐P10 treatment from the medical records of 389 patients with DLBCL (24 centers, five European countries). For the primary outcome (clinical effectiveness), overall survival (OS), progression‐free survival (PFS), and best response (BR) were assessed. The percentage (95% confidence interval [95% CI]) of patients alive at 12‐, 18‐, and 30 months postindex (initiation of CT‐P10) was 86% (82.4%–89.4%), 81% (76.9%–84.9%), and 76% (71.2%–80.1%), respectively. The PFS rate (percent, [95% CI]) at 12‐, 18‐, and 30 months postindex was 78% (74.2%–82.5%), 72% (67.9%–76.9%), and 67% (61.9%–71.7%), respectively. Median OS/PFS was not reached. For 82% (n = 312) of patients, the BR to CT‐P10 was a complete response. Adverse events were consistent with known effects of chemotherapy. This international, multicenter study provides real‐world data on the safety and effectiveness profile of CT‐P10 for DLBCL treatment and supports the adoption of CT‐P10 for the treatment of DLBCL.

Published
2023
Full Text
View/download PDF

23. S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)

Author

C. Carlo-Stella, S. Ansell, P. L Zinzani, J. Radford, K. Maddocks, A. Pinto, G. P. Collins, V. Bachanova, N. Bartlett, I. Bence-Bruckler, M. Hamadani, J. Kline, J. Mayer, K. J. Savage, R. Advani, P. Caimi, R.-O. Casasnovas, T. Feldman, B. Hess, M. Bastos-Oreiro, S. Iyengar, S. Eisen, Y. Negievich, L. Wang, J. Wuerthner, and A. F. Herrera

Subjects
Hematology
Published
2022

24. T-Cell Project: an international, longitudinal, observational study of patients with aggressive peripheral T-cell lymphoma Projeto de célula-T: estudo internacional, longitudinal de pacientes com linfoma de célula-T periférica agressivo

Author

Massimo Federico, Monica Bellei, Emanuela Pesce, Emanuele Zucca, Stefano Pileri, Silvia Montoto, Dennis D Weisenburger, Thomas Ruediger, Y. H. Ko., Raymond Liang, Pier L. Zinzani, Joseph M. Connors, Francine M. Foss, Steven M. Horwitz, Aaron Polliack, and Julie M. Vose

Subjects
Linfomas-T, evolução, quimioterapia, epidemiologia, T-cell lymphoma, outcome, chemotherapy, epidemiology, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of neoplasms that are derived from post-thymic lymphoid cells at different stages of differentiation and with different morphological patterns, phenotypes, and clinical presentations. PTCLs are highly diverse, reflecting the diverse cells from which they can originate and are currently sub-classified using World Health Organization (WHO) 2008 criteria. Peripheral T-Cell Lymphomas account for 5%-10% of all lymphoproliferative disorders in the Western hemisphere, with an overall incidence of 0.5-2 per 100,000 individuals per year, and have a striking epidemiological distribution, with higher incidence in Asia. The clinical features of PTCL are extremely heterogeneous. PTCLs express even more clinical diversity than B-cell non-Hodgkin's lymphomas, and there is a close, though not absolute, relationship between some unusual clinical features and certain histological subtypes.Linfomas T periféricos (PTCLs) compreendem um grupo heterogêneo de neoplasias que derivam das células linfoides pós-tímicas nos diversos estágios de maturação, com diversos padrões histológicos, fenotípicos, e clínicos. PTCLs são muito diversos entre si e refletem diversas células das quais foram originadas e são atualmente subclassificadas, usando-se a classificação da Organização Mundial da Saúde (OMS) 2008, apresentada neste texto na tabela 1. PTCLs compreendem 5%-10% de todas as doenças linfoproliferativas no mundo ocidental, com uma incidência global de 0.5 a 2 a cada 100.000 pessoas por ano e têm uma distribuição epidemiológica diversa com maior incidência na Ásia. Os achados clínicos dos PTCLs são muito heterogêneos. PTCLs expressam muito maior variação de apresentações clínicas do que os linfomas B, e há uma íntima, mas não absoluta, relação entre algum achado clínico não usual e certos subtipos histológicos. O autor faz aqui uma revisão do assunto altamente contemporâneo

Published
2009
Full Text
View/download PDF

25. LOTIS 2 FOLLOW‐UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Author

Carmelo Carlo-Stella, Juan Pablo Alderuccio, Mehdi Hamadani, Brad S. Kahl, John Radford, Brian T. Hess, Yajuan Qin, Shui He, Anastasios Stathis, P. L. Zinzani, David Ungar, Jay Feingold, W. Y. Ai, Melhem Solh, Kirit M. Ardeshna, and Paolo Caimi

Subjects
Cancer Research, medicine.medical_specialty, Oncology, business.industry, medicine, Phases of clinical research, Refractory Diffuse Large B-Cell Lymphoma, Hematology, General Medicine, Radiology, business
Published
2021

26. CHRONOS‐3: RANDOMIZED PHASE III STUDY OF COPANLISIB PLUS RITUXIMAB VS RITUXIMAB/PLACEBO IN RELAPSED INDOLENT NON‐HODGKIN LYMPHOMA (INHL)

Author

Aruna Mehra, L. Mongay Soler, Árpád Szomor, Muhit Ozcan, Qingyuan Zhang, Eduardo Yanez, Barrett H. Childs, Jie Jin, P. L. Zinzani, Rinat Galiulin, Florian Hiemeyer, Klaus Geissler, Igor Bondarenko, Ross I. Baker, Toshiki Uchida, Kamal Bouabdallah, Wojciech Jurczak, Anjun Cao, Jifeng Feng, Wei Li, Fangfang Lv, Aryan Hamed, M. Matasar, T. Lin, Mihaela Lazaroiu, Güray Saydam, Katya Sapunarova, Yuankai Shi, Ming-Chung Wang, and Marcelo Capra

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, Placebo, chemistry.chemical_compound, chemistry, Internal medicine, Indolent Non-Hodgkin Lymphoma, Medicine, Rituximab, business, Copanlisib, medicine.drug
Published
2021

27. PATIENT‐REPORTED QUALITY OF LIFE (QOL) FOLLOWING TISAGENLECLEUCEL (TISA‐CEL) INFUSION IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)

Author

Leslie Popplewell, Charalambos Andreadis, Catherine Thieblemont, Andrés J.M. Ferreri, Hideo Harigae, Arne Kolstad, Phoebe Joy Ho, Fritz Offner, Aisha Masood, Ranjan Tiwari, Jie Zhang, Piers Em Patten, Jose Antonio Pérez Simón, L. J. Nastoupil, Kouji Kato, Stephen J. Schuster, M. Dreyling, Takanori Teshima, Ram Malladi, Andreas L. Petzer, Bastian von Tresckow, Monalisa Ghosh, Nathan Fowler, Joseph P. McGuirk, Peter A. Riedell, Joaquin Martinez-Lopez, Jason Butler, P. L. Zinzani, Andreas Viardot, Emmanuel Bachy, M. José Kersten, Michael Dickinson, Julio C. Chavez, and Vamsi Bollu

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Adult patients, business.industry, Follicular lymphoma, Hematology, General Medicine, medicine.disease, Quality of life, Internal medicine, Relapsed refractory, medicine, business
Published
2021

28. BEGEV SALVAGE REGIMEN IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A REAL‐LIFE EXPERIENCE

Author

G. Bagnato, Vittorio Stefoni, Laura Nanni, M. Gentilini, Paolo Elia Coppola, Alice Morigi, P. L. Zinzani, Lisa Argnani, Alessandro Broccoli, Cinzia Pellegrini, Matteo Carella, Beatrice Casadei, and Ginevra Lolli

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Internal medicine, Relapsed refractory, Salvage regimen, medicine, Classical Hodgkin lymphoma, Hematology, General Medicine, business
Published
2021

29. NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY

Author

Neha Mehta-Shah, Pauline Brice, Justin Kline, John Kuruvilla, Paul M. Barr, David Cunningham, Nathalie A. Johnson, Giuseppe Gritti, Armando Santoro, Michelle A. Fanale, P. L. Zinzani, A.J. Moskowitz, and Stephen Francis

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Checkmate, Hematology, General Medicine, Internal medicine, Relapsed refractory, medicine, Primary Mediastinal Large B-Cell Lymphoma, Nivolumab, Brentuximab vedotin, business, medicine.drug
Published
2021

30. HEALTH‐RELATED QUALITY OF LIFE AMONG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) IN A PHASE 3 STUDY OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN

Author

Robin Gasiorowski, Michael Dickinson, John Kuruvilla, Monika Raut, Nathalie A. Johnson, Armando Santoro, Valeria Buccheri, Muhit Ozcan, Alice McDonald, Hilde Giezek, Todd L. Saretsky, Ewa Paszkiewicz-Kozik, P. L. Zinzani, Akash Nahar, Guilherme Fleury Perini, Naohiro Sekiguchi, J. S. R. de Oliveira, and Radhakrishnan Ramchandren

Subjects
Health related quality of life, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Phases of clinical research, Hematology, General Medicine, Pembrolizumab, Internal medicine, Relapsed refractory, medicine, Classical Hodgkin lymphoma, Brentuximab vedotin, business, medicine.drug
Published
2021

31. A NON‐INTERVENTIONAL STUDY OF OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (URBAN): IMPACT OF COVID‐19 PANDEMIC ON ENROLLMENT AND SAFETY

Author

A ., P. L . Zinzani, L . Arcaini, G . Gritti, C . Patti, E . Pennese, S . De Lorenzo, C . Piparo, E . Guardalben, and M . Ladetto

Subjects
Oncology, Cancer Research, medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Follicular lymphoma, Hematology, General Medicine, medicine.disease, chemistry.chemical_compound, chemistry, Obinutuzumab, Internal medicine, Pandemic, Non interventional, Medicine, Publication, In patient, SUPPLEMENT: 16th INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA, VIRTUAL EDITION, 18–22 JUNE, 2021, Supplement Abstract, business
Published
2021

32. CLADRIBINE AS FRONTLINE TREATMENT OF HAIRY CELL LEUKEMIA: A MULTICENTER EUROPEAN EXPERIENCE OF MORE THAN 30 YEARS ON 384 PATIENTS

Author

Daniel Catovsky, Lisa Argnani, E. Maitre, A. Janus, P. L. Zinzani, Xavier Troussard, Monica Else, Tadeusz Robak, Claire Dearden, M. Cross, and Alessandro Broccoli

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, medicine.disease, Internal medicine, medicine, Hairy cell leukemia, business, Cladribine, medicine.drug
Published
2021

33. LACUTAMAB IN PATIENTS (PTS) WITH ADVANCED MYCOSIS FUNGOIDES (MF) ACCORDING TO KIR3DL2 EXPRESSION: EARLY RESULTS FROM THE TELLOMAK PHASE 2 TRIAL

Author

F. Rotolo, Olivier Dereure, Stéphane Dalle, P. L. Zinzani, Youn H. Kim, Marie Beylot-Barry, H. A Azim, L. Mortier, P L Ortiz-Romero, Martine Bagot, Eric N. Jacobsen, Pierluigi Porcu, and A. Cambalia

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Mycosis fungoides, business.industry, Hematology, General Medicine, medicine.disease, Early results, KIR3DL2, Internal medicine, medicine, In patient, business
Published
2021

34. ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY

Author

Mengjun Wang, Jehan Dupuis, T. Lamy, Andrew Davies, Carlos Panizo, Tadeusz Robak, Eric N. Jacobsen, Lucie Oberic, S. Le Gouill, Simon Rule, Richard Eek, Arnon P. Kater, Monika Długosz-Danecka, O. Casasnovas, Roser Calvo, J.K. Doorduijn, Preetesh Jain, F. Morschhauser, Stephen D. Smith, Lin Tao, Bhavana Shah, Ghandi Damaj, P. L. Zinzani, and Andre Goy

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Phases of clinical research, Hematology, General Medicine, medicine.disease, Internal medicine, Relapsed refractory, medicine, Acalabrutinib, In patient, Mantle cell lymphoma, business
Published
2021

35. A PHASE 2 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE (LONCA) VERSUS (VS) IDELALISIB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) – LOTIS‐6

Author

L. Wang, Carmelo Carlo-Stella, Brian T. Hess, P. L. Zinzani, D. Ungar, Kirit M. Ardeshna, V. Dai, J. Depaus, and E. Kingsley

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Follicular lymphoma, Hematology, General Medicine, medicine.disease, Gastroenterology, law.invention, Oncology, Randomized controlled trial, Refractory, law, Internal medicine, medicine, In patient, Idelalisib, business
Published
2021

36. MOLTO, A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CLINICAL TRIAL ON VENETOCLAX, ATEZOLIZUMAB, OBINUTUZUMAB IN RICHTER TRANSFORMATION: SAFETY INTERIM ANALYSIS

Author

Marina Motta, Anna Maria Frustaci, Alessandra Tedeschi, Marina Deodato, D. Rossi, P. L. Zinzani, Gianluca Gaidano, Marco Montillo, Roberto Cairoli, Marta Coscia, Giulia Zamprogna, Candida Vitale, Daniela Pietrasanta, Thorsten Zenz, and Lydia Scarfò

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Richter transformation, business.industry, Venetoclax, Hematology, General Medicine, Interim analysis, Clinical trial, chemistry.chemical_compound, chemistry, Obinutuzumab, Atezolizumab, Internal medicine, Medicine, Open label, business
Published
2021

37. CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)

Author

Kerry J. Savage, Jens Wuerthner, Justin Kline, Mehdi Hamadani, P. L. Zinzani, L. Wang, Kami J. Maddocks, Graham P. Collins, S. M. Ansell, Carmelo Carlo-Stella, Paolo Caimi, Hans G Cruz, Y. Negievich, Nancy L. Bartlett, John Radford, and Alex F. Herrera

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Phases of clinical research, Hematology, General Medicine, Immunotherapy, Refractory, Internal medicine, medicine, Classical Hodgkin lymphoma, Hodgkin lymphoma, Open label, business
Published
2021

38. GUT MICROBIOTA ROLE IN RESPONSE TO CHECKPOINT INHIBITOR TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL HODGKIN LYMPHOMA: AN INTERIM ANALYSIS FROM MICRO‐LINF STUDY

Author

P. L. Zinzani, Lisa Argnani, Silvia Turroni, Serafina Guadagnuolo, Beatrice Casadei, Patrizia Brigidi, and Monica Barone

Subjects
Cancer Research, biology, business.industry, Immune checkpoint inhibitors, Hematology, General Medicine, Gut flora, Interim analysis, biology.organism_classification, medicine.anatomical_structure, Oncology, Relapsed refractory, Cancer research, medicine, Hodgkin lymphoma, In patient, business, B cell
Published
2021

39. GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA

Author

D. Piffaretti, Manuela Mollejo, L. Terzi di Bergamo, M. G. Cittone, Liliana Devizzi, Guido Ghilardi, Estella Matutes, Elena Sabattini, Elisa Lucchini, Sílvia Beà, Lydia Scarfò, Sergio Cogliatti, Stefano Pileri, Davide Rossi, M. Án. Piris, Govind Bhagat, Gilles Salles, Armando López-Guillermo, Maria Joao Baptista, Emanuele Zucca, Alden A. Moccia, Alessandra Tucci, Vincenzo Canzonieri, M. Ladetto, Luca Arcaini, Renzo Boldorini, Gabriela Forestieri, Maria Cristina Pirosa, Elias Campo, Alessandro Broccoli, Thomas Tousseyn, Sascha Dietrich, Roberto Marasca, Gianluca Gaidano, Ricardo Koch, Enrico Derenzini, Fabio Facchetti, Juan F. García, Alexandar Tzankov, Michele Merli, Carlo Visco, Hossein Khiabanian, Francesca Guidetti, Franco Cavalli, Arianna Calcinotto, Francesco Passamonti, Thorsten Zenz, Giuseppe Gritti, Julia T. Geyer, Marco Lucioni, M. Ponzoni, M. Faderl, Francesco Bertoni, Anastasios Stathis, Antonino Maiorana, Urban Novak, L. de Leval, Alexandra Traverse-Glehen, Luca Mazzucchelli, Anna Guidetti, Gabriela Bastidas, Véronique Meignin, P. L. Zinzani, Luciano Cascione, Ferdinando Bonfiglio, Giorgio Inghirami, Felicitas Hitz, Stefano Pizzolitto, Alberto J. Arribas, Angela Rita Elia, Elisa Santambrogio, Georg Stussi, Catherine Thieblemont, David Oscier, Marco Paulli, Bernhard Gerber, Umberto Vitolo, Alessio Bruscaggin, Francesco Piazza, Stefan Dirnhofer, W. Wu, Paolo Ghia, Valeria Spina, L. Bonomini, K. Pini, Gustavo Tapia, M. G. Da Silva, Luca Ceriani, Carlos Montalbán, and Adalgisa Condoluci

Subjects
Cancer Research, Pathology, medicine.medical_specialty, Oncology, medicine, Hematology, General Medicine, Splenic marginal zone lymphoma, Biology, medicine.disease, Phenotype
Published
2021

40. NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY

Author

John Kuruvilla, Paul J Bröckelmann, P. L. Zinzani, S. M. Ansell, Hun J. Lee, Jonathon B. Cohen, Rene Swanink, Ulrich Jaeger, Wolfgang Willenbacher, Andreas Engert, J.P. de Boer, Graham P. Collins, Armando Santoro, Marek Trneny, Margaret A. Shipp, Mariana Sacchi, Kerry J. Savage, Mariano Provencio, G. von Keudell, and P. Armand

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Checkmate, Hematology, General Medicine, Refractory, Internal medicine, medicine, Overall survival, Classical Hodgkin lymphoma, Autologous transplantation, Nivolumab, business
Published
2021

41. FDG‐PET IMAGING AND RADIOMICS IN RESPONSE ASSESSMENT OF LYMPHOMA PATIENTS UNDERGOING CAR T‐CELL THERAPY

Author

Serafina Guadagnuolo, M. Santoro, Beatrice Casadei, Andrea Paccagnella, A. Farolfi, Lidia Strigari, P. L. Zinzani, Stefano Fanti, G. Paolani, C. Malizia, Francesca Bonifazi, S. Strolin, Lisa Argnani, and G. Della Gala

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, medicine.disease, Lymphoma, Response assessment, Oncology, Radiomics, medicine, CAR T-cell therapy, Radiology, business
Published
2021

42. FIRST REPORT OF THE REAL‐LIFE PROSPECTIVE OBSERVATIONAL STUDY 'CAR‐T CELL IN DIFFUSE LARGE B‐CELL AND PRIMARY MEDIASTINAL LYMPHOMAS' OF THE ITALIAN SOCIETY OF HEMATOLOGY

Author

Anna Guidetti, Maria Chiara Tisi, Rosalba Miceli, Matteo Carrabba, P. L. Zinzani, Patrizia Chiusolo, A. Di Rocco, Massimo Martino, Beatrice Casadei, Anna Maria Barbui, Paolo Corradini, Anna Dodero, C. Carniti, Annalisa Chiappella, Armando Santoro, and Stefania Bramanti

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Hematology, business.industry, General Medicine, medicine.anatomical_structure, Internal medicine, medicine, Observational study, Car t cells, business, B cell
Published
2021

43. SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY)

Author

J. Trotman, A. Tedeschi, K. Linton, P. McKay, B. Hu, H. Chan, J. Jin, M. Sobieraj‐Teague, P. L. Zinzani, M. Coleman, P. Browett, X. Ke, M. Sun, R. Marcus, C. Portell, C. Thieblemont, K. Zhou, A. M. Liberati, E. Bachy, F. Cavallo, Rég. Costello, S. Iyengar, R. Marasca, H. Mociková, J. S. Kim, D. Talaulikar, M. Co, W. Zhou, J. Huang, and S. Opat

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Marginal zone lymphoma, Phases of clinical research, Hematology, General Medicine, immune system diseases, hemic and lymphatic diseases, Internal medicine, Relapsed refractory, medicine, Indolent Non-Hodgkin Lymphoma, In patient, business
Abstract

Background: BCR signaling mediated through Bruton's tyrosine kinase (BTK) plays a critical role in the development and maintenance of marginal zone lymphoma (MZL). BTK inhibitors have established activity in relapsed/refractory (R/R) MZL with the phase 2 study of ibrutinib demonstrating an objective response rate (ORR) of 48% (Noy et al. Blood. 2017;129:2224-2232).

Published
2021

44. PROGNOSTIC FACTORS, MANAGEMENT AND OUTCOME OF AN INTERNATIONAL SERIES OF 41 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) AND CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT

Author

M. Ponzoni, Piera Angelillo, M. M.B Salvador Chalup, C. Muzi, Maria Dimou, Potito Rosario Scalzulli, F. L. Nogueira, Emilio Iannitto, D. Onofrillo, Anna Ferreri, Marco Foppoli, Monica Tani, F. Cocito, P. Ramakrishnan, Alessia Castellino, T. Calimeri, Vittoria Tarantino, P. L. Zinzani, Kate Cwynarski, Alessandra Tucci, Felicetto Ferrara, T.P. Vassilakopoulos, G. Cabras, Andrew Davies, Luigi Petrucci, Andrea Ferrario, Sotirios G. Papageorgiou, Maria Chiara Tisi, and Luca Arcaini

Subjects
Oncology, Cancer Research, Series (stratigraphy), medicine.medical_specialty, business.industry, Central nervous system, CNS Involvement, Hematology, General Medicine, medicine.anatomical_structure, Internal medicine, medicine, Primary Mediastinal Large B-Cell Lymphoma, business
Published
2021

45. CLINICAL ACTIVITY OF LONCASTUXIMAB TESIRINE PLUS IBRUTINIB IN NON‐HODGKIN LYMPHOMA: UPDATED LOTIS 3 PHASE 1 RESULTS

Author

S. De Guibert, Tycel Phillips, Xiaomin He, Murali Janakiram, Julien Depaus, Silvia Ferrari, Carmelo Carlo-Stella, Joseph Boni, Locke J. Bryan, Karin Havenith, Monica Tani, Annette Ervin-Haynes, Emmanuel Bachy, P. L. Zinzani, Nina Wagner-Johnston, Joseph Maly, Vivian Dai, and Vincent Delwail

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Hematology, General Medicine, chemistry.chemical_compound, chemistry, Internal medicine, Phase (matter), Ibrutinib, medicine, Hodgkin lymphoma, business
Published
2021

46. Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Author

Won Seog Kim, Muhit Ozcan, Roncero Jm, Tamás Masszi, Anne Lennard, Eric D. Jacobsen, Steven M. Horwitz, Lorenz Trümper, Juliana Pereira, EJ Leonard, Francine M. Foss, Anne W. Beaven, John P. Leonard, Karthik Venkatakrishnan, Rod Ramchandren, C.S. Chiattone, Mehmet Turgut, Claudio Dansky Ullmann, Lumiere Study Investigators, Owen A. O'Connor, Judith Trotman, Judit Demeter, Andrei R. Shustov, Hua Liu, Nelson Hamerschlak, Sheldon-Waniga E, Eric D. Hsi, Francesco d'Amore, Dolores Caballero, P. L. Zinzani, O'Connor, Owen A, Özcan, Muhit, Jacobsen, Eric D, Roncero, Josep M, Trotman, Judith, Demeter, Judit, Masszi, Tamá, Pereira, Juliana, Ramchandren, Radhakrishnan, Beaven, Anne, Caballero, Dolore, Horwitz, Steven M, Lennard, Anne, Turgut, Mehmet, Hamerschlak, Nelson, d'Amore, Francesco A, Foss, Francine, Kim, Won-Seog, Leonard, John P, Zinzani, Pier Luigi, Chiattone, Carlos S, Hsi, Eric D, Trümper, Lorenz, Liu, Hua, Sheldon-Waniga, Emily, Ullmann, Claudio Dansky, Venkatakrishnan, Karthik, Leonard, E Jane, Shustov, Andrei R, Lumiere Study Investigators, and OMÜ

Subjects
Male, Oncology, PHARMACOKINETICS, Cancer Research, Time Factors, KINASE INHIBITOR ALISERTIB, chemistry.chemical_compound, 0302 clinical medicine, AURORA KINASE, Recurrence, Single agent, Aurora Kinase A, Aged, 80 and over, Refractory Peripheral T-cell Lymphoma, 0303 health sciences, MLN8237, ORIGINAL REPORTS, Azepines, Middle Aged, APOPTOSIS, 3. Good health, 030220 oncology & carcinogenesis, Early Termination of Clinical Trials, Disease Progression, AUTOPHAGY, Female, EPITHELIAL OVARIAN, Adult, medicine.medical_specialty, Aurora A kinase, Antineoplastic Agents, Peripheral T-Cell Lymphoma, Alisertib, Disease-Free Survival, SIGNALING PATHWAYS, Young Adult, 03 medical and health sciences, Internal medicine, Hematologic Malignancy, medicine, BREAST-CANCER, Humans, In patient, Protein Kinase Inhibitors, Aged, 030304 developmental biology, MESENCHYMAL TRANSITION, business.industry, Lymphoma, T-Cell, Peripheral, Pyrimidines, chemistry, Drug Resistance, Neoplasm, Alisertib, business
Abstract

PEREIRA, JULIANA/0000-0002-0655-2821; ZINZANI, PIER LUIGI/0000-0002-2112-2651; Trotman, Judith/0000-0001-8009-4593 WOS: 000462407900001 PubMed: 30707661 PURPOSEThe aim of this open-label, first-in-setting, randomized phase III trial was to evaluate the efficacy of alisertib, an investigational Aurora A kinase inhibitor, in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL).PATIENTS AND METHODSAdult patients with relapsed/refractory PTCLone or more prior therapywere randomly assigned 1:1 to receive oral alisertib 50 mg two times per day (days 1 to 7; 21-day cycle) or investigator-selected single-agent comparator, including intravenous pralatrexate 30 mg/m(2) (once per week for 6 weeks; 7-week cycle), or intravenous gemcitabine 1,000 mg/m(2) or intravenous romidepsin 14 mg/m(2) (days 1, 8, and 15; 28-day cycle). Tumor tissue (disease subtype) and imaging were assessed by independent central review. Primary outcomes were overall response rate and progression-free survival (PFS). Two interim analyses and one final analysis were planned.RESULTSBetween May 2012 and October 2014, 271 patients were randomly assigned (alisertib, n = 138; comparator, n = 133). Enrollment was stopped early on the recommendation of the independent data monitoring committee as a result of the low probability of alisertib achieving PFS superiority with full enrollment. Centrally assessed overall response rate was 33% for alisertib and 45% for the comparator arm (odds ratio, 0.60; 95% CI, 0.33 to 1.08). Median PFS was 115 days for alisertib and 104 days for the comparator arm (hazard ratio, 0.87; 95% CI, 0.637 to 1.178). The most common adverse events were anemia (53% of alisertib-treated patients v 34% of comparator-treated patients) and neutropenia (47% v 31%, respectively). A lower percentage of patients who received alisertib (9%) compared with the comparator (14%) experienced events that led to study drug discontinuation. Of 26 on-study deaths, five were considered treatment related (alisertib, n = 3 of 11; comparator, n = 2 of 15). Two-year overall survival was 35% for each arm.CONCLUSIONIn patients with relapsed/refractory PTCL, alisertib was not statistically significantly superior to the comparator arm. Millennium Pharmaceuticals, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Funded by Millennium Pharmaceuticals, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Published
2019

47. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial

Author

Amy Musiek, M. C. Medley, Richard A Cowan, Francine M. Foss, P. L. Zinzani, Reinhard Dummer, J. P Rosen, Jan P. Nicolay, Julia Scarisbrick, Lauren C. Pinter-Brown, Lubomir Sokol, Lars Iversen, Pietro Quaglino, Takahiro Ito, University of Zurich, Cowan, R A, Cowan R.A., Scarisbrick J.J., Zinzani P.L., Nicolay J.P., Sokol L., Pinter-Brown L., Quaglino P., Iversen L., Dummer R., Musiek A., Foss F., Ito T., Rosen J.-P., and Medley M.C.

Subjects
Skin Neoplasms, business.operation, Tumor burden, 610 Medicine & health, Dermatology, Antibodies, Monoclonal, Humanized, Antibodies, 2708 Dermatology, Mycosis Fungoides, Humans, Neoplasm Recurrence, Local, Tumor Burden, Monoclonal, Medicine, Humanized, Mycosis Fungoide, business.industry, 10177 Dermatology Clinic, Mallinckrodt, 2725 Infectious Diseases, Management, Neoplasm Recurrence, Infectious Diseases, Local, business, Human
Abstract

RC is a consultant for Kyowa Kirin and served on an advisory board for Helsinn. JJS is a consultant for Kyowa Kirin, Takeda, Recordat, 4SC, Innate Pharma and Helsinn. She received a 1-year educational grant from Kyowa Kirin for work on quality of life in CTCL. She also has membership on an entity’s Board of Directors or advisory committees for Kyowa Kirin, Takeda, 4SC, Innate Pharma, Miragen and Helsinn. PLZ has received honoraria from MSD, Celltrion, Gilead, Janssen-Cilag, BMS and TG Therapeutics. He is also a consultant for MSD, EUSA Pharma, Sanofi and Verastem. He also has membership on an entity’s Board of Directors or advisory committees for MSD, Eusa Pharma, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, Sandoz, Immune Design, Celgene, Portola, Roche, Kyowa Kirin, TG Therapeutics, and Verastem. He has also been on a Speakers Bureau for MSD, EUSA Pharma, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, Immune Design, Celgene, Portola, Roche, Kyowa Kirin and Verastem. JPN has received honoraria from Pharmaceutical Industries, TEVA, Novartis AG, Biogen GmbH, Almirall Hermal AG, Actelion Pharmaceuticals, UCB Pharma, LaRoche Posay, Takeda Pharmaceuticals and Kyowa Kirin. He is also a consultant for Novartis AG, Biogen GmbH, Almirall Hermal AG, Actelion Pharmaceuticals, Innate Pharma, Kyowa Kirin and Takeda Pharmaceuticals. He has also received grants and personal fees from Pharmaceutical Industries outside of the submitted work. LS is a consultant for Dren Bio and served on an advisory board for Kyowa Kirin, Kymera Therapeutics and EUSA Pharma. LP-B has been an advisory board for Epizyme, Morphosys, Helsinn, Verastem and Actelion. She is also a consultant for Acrotech. PQ has received honoraria from Actelion, Innate Pharma, Takeda, Kyowa Kirin, Helsinn and Therakos. He also been on an advisory board for Actelion, Innate Pharma, Takeda, Kyowa Kirin, Helsinn and Therakos. LI has served as a consultant and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, Janssen-Cilag, Kyowa Kirin, LEO Pharma, MSD, Novartis, Pfizer, Sun Pharma and UCB. RD is a consultant for Merck Sharp & Dohme, Novartis, Bristol-Myers Squibb, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym and Second Genome. AM is an investigator for Menlo, Soligenix, Pfizer, Elorac and miRagen. She has also received honoraria from Kyowa Kirin. She also has a membership on an entity’s Board of Directors or advisory committees for Helsinn. FF has received honoraria from Seagen, Mallinckrodt and Kyowa Kirin. She is also a consultant for Miragen. She had also served on a Data Safety Monitoring Board for Celgene. She was also the President of the US Cutaneous Lymphoma Consortium. TI is an employee of Kyowa Kirin, Inc. J-PR is an employee of Kyowa Kirin, Inc. MCM is an employee of Kyowa Kirin, Inc.

Published
2021

48. 826O Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the phase III CHRONOS-3 trial

Author

P. Panayiotidis, M. Matasar, A.M. Tyczynska, Árpád Szomor, Jie Jin, Barrett H. Childs, P. L. Zinzani, Dok Hyun Yoon, L. Mongay Soler, Muhit Ozcan, Anjun Cao, and Florian Hiemeyer

Subjects
medicine.medical_specialty, business.industry, Marginal zone lymphoma, Hematology, Placebo, Gastroenterology, chemistry.chemical_compound, Oncology, chemistry, Internal medicine, medicine, In patient, Rituximab, business, Copanlisib, medicine.drug
Published
2021

49. Novel Therapies for Aggressive B-Cell Lymphoma

Author

Kenneth A. Foon, Kenichi Takeshita, and Pier L. Zinzani

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Aggressive B-cell lymphoma (BCL) comprises a heterogeneous group of malignancies, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, and mantle cell lymphoma (MCL). DLBCL, with its 3 subtypes, is the most common type of lymphoma. Advances in chemoimmunotherapy have substantially improved disease control. However, depending on the subtype, patients with DLBCL still exhibit substantially different survival rates. In MCL, a mature B-cell lymphoma, the addition of rituximab to conventional chemotherapy regimens has increased response rates, but not survival. Burkitt lymphoma, the most aggressive BCL, is characterized by a high proliferative index and requires more intensive chemotherapy regimens than DLBCL. Hence, there is a need for more effective therapies for all three diseases. Increased understanding of the molecular features of aggressive BCL has led to the development of a range of novel therapies, many of which target the tumor in a tailored manner and are summarized in this paper.

Published
2012
Full Text
View/download PDF

50. CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B-CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL

Author

Christopher Major, Louis M. Staudt, P. Johnson, Brendan P. Hodkinson, Jessica Vermeulen, Jodi Carey, Michael Schaffer, M. Shreeve, Shean-Sheng Wang, Walter R. Wilson, Anas Younes, Steven Sun, Grace Liu, C. Loefgren, P. L. Zinzani, Laurie H. Sehn, Sen Hong Zhuang, and Sriram Balasubramanian

Subjects
Gene expression profiling, Cancer Research, Oncology, Concordance, medicine, Immunohistochemistry, Hematology, General Medicine, Biology, medicine.disease, Molecular biology, Diffuse large B-cell lymphoma, Subtyping
Published
2019

Catalog

Books, media, physical & digital resources
See catalog results